A Phase I Dose Escalation Study of MLN8237, an Aurora a

Project: Research project

Description

A Phase I Dose Escalation Study of MLN8237, an Aurora A Kinase Inhibitor, in Adult Patietns with Nonhematological Malignancies, followed by a Phase 2 of MLN8237 in Lung, Breast, Head and Neck, or Gastroesophageal Malignancies
StatusFinished
Effective start/end date8/31/108/31/14

Funding

  • MILLENNIUM PHARMACEUTICALS, INC.

Fingerprint

Aurora Kinase A
Breast
Neck
Head
Lung
Neoplasms
MLN 8237